L
Lewis J. Rubin
Researcher at University of California, San Diego
Publications - 373
Citations - 60316
Lewis J. Rubin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Bosentan. The author has an hindex of 101, co-authored 370 publications receiving 57044 citations. Previous affiliations of Lewis J. Rubin include University of Texas Health Science Center at San Antonio & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Pathology and pathophysiology of primary pulmonary hypertension.
TL;DR: Primary pulmonary hypertension is characterized by extensive remodeling of the pulmonary vasculature, with consequent deleterious hypertrophic changes in the right ventricle, and primarily affects young to middle-aged women.
Journal ArticleDOI
The natural history of acute and chronic thromboembolic disease: the search for the missing link
TL;DR: The frequency with which evidence of prior pulmonary embolism can be found on careful dissection of the pulmonary arteries suggests that asymptomatic events may occur commonly and that complete thromboembolic resolution following an acute embolic event may represent the exception rather than the rule.
Journal ArticleDOI
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
Sean Gaine,Kelly Chin,Gerry Coghlan,Richard N. Channick,Lilla Di Scala,Nazzareno Galiè,Hossein Ardeschir Ghofrani,Hossein Ardeschir Ghofrani,Irene M. Lang,Vallerie V. McLaughlin,R Preiss,Lewis J. Rubin,Gérald Simonneau,Gérald Simonneau,Olivier Sitbon,Olivier Sitbon,Victor F. Tapson,Marius M. Hoeper +17 more
TL;DR: Selexipag delayed progression of PAH and was well-tolerated amongPAH-CTD patients, including those with PAH-SSc and PAH,SLE, and the overall GRIPHON population.
Journal ArticleDOI
Temporal trends and drug exposures in pulmonary hypertension: an American experience.
Alexander M. Walker,David Langleben,James Korelitz,Stuart Rich,Lewis J. Rubin,Brian L. Strom,René Gonin,Susan Keast,David B. Badesch,Robyn J. Barst,Robert C. Bourge,Richard N. Channick,Adaani E. Frost,Sean Gaine,Sean Gaine,Michael D. McGoon,Vallerie V. McLaughlin,Srinivas Murali,Ronald J. Oudiz,Ivan M. Robbins,Victor F. Tapson,Lucien Abenhaim,Ginger Constantine +22 more
TL;DR: In this article, the authors established a surveillance network within the United States to monitor temporal trends in the number of reported cases of pulmonary arterial hypertension (PAH) and studied whether use of anorexigens and other drugs differed among patients with pulmonary hypertension of different etiologies.
Journal ArticleDOI
Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
David B. Badesch,Michael D. McGoon,R.J. Barst,Victor F. Tapson,Lewis J. Rubin,Fredrick M. Wigley,Kenneth M. Kral,Ibrahim Raphiou,Glenn Crater +8 more
TL;DR: This study reports a better survival outcome than natural history data on patients with scleroderma-associated PAH treated with IV epoprostenol in an uncontrolled open-label 3-year extension study following an initial randomized, controlled 12-week study.